|
Market Closed -
Nasdaq
20:00:00 26/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 1.070 USD | -3.60% |
|
-4.46% | -54.08% |
| 08-12 | Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Spero Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 517.5 | 89.57 | 77.91 | 56.15 | 131.3 | 62.31 | - |
| Change | - | -82.69% | -13.02% | -27.92% | 133.77% | -52.53% | - |
| Enterprise Value (EV) | 371.1 | 89.57 | 77.91 | 56.15 | 131.3 | 62.31 | 62.31 |
| Change | - | -75.86% | -13.02% | -27.92% | 133.77% | -52.53% | 0% |
| P/E | -5.5x | -1.41x | 3.42x | -0.81x | 15.5x | -1.84x | -10.2x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | 0x | -0x | 0x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 28.3x | 1.67x | 0.75x | 1.17x | - | 242x | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | 242x | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | - | -1.7x | -1.13x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -2.91 | -1.23 | 0.43 | -1.27 | 0.15 | -0.58 | -0.105 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 18.26 | 53.51 | 103.8 | 47.98 | - | 0.258 | - |
| EBITDA | -87.32 | - | - | - | - | - | - |
| EBIT 1 | -87.97 | -42.2 | 21.48 | -73.36 | - | -36.66 | -55 |
| Net income 1 | -89.76 | -46.42 | 22.81 | -68.57 | - | -33.46 | -51.5 |
| Net Debt | -146.4 | - | - | - | - | - | - |
| Reference price 2 | 16.010 | 1.730 | 1.470 | 1.030 | 2.330 | 1.070 | 1.070 |
| Nbr of stocks (in thousands) | 32,324 | 51,776 | 52,999 | 54,518 | 56,339 | 58,235 | - |
| Announcement Date | 31/03/22 | 30/03/23 | 13/03/24 | 27/03/25 | 26/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.84x | - | - | - | 62.31M | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.04x | 7.96x | 26.09x | 0.05% | 54.57B | |
| 36.97x | 6.56x | 19.6x | 0.88% | 53.59B | |
| 34.86x | 3.39x | 14.64x | -.--% | 45.03B | |
| 48.82x | 5.62x | 30.9x | -.--% | 42.17B | |
| -19.09x | 184.46x | -20.29x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.72x | 5.84x | 15.15x | -.--% | 24.01B | |
| 36.39x | 6.61x | 22.07x | -.--% | 26.5B | |
| Average | 24.02x | 26.11x | 15.76x | 0.34% | 38.33B | |
| Weighted average by Cap. | 26.69x | 24.66x | 15.94x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SPRO Stock
- Valuation Spero Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
